Feast or Famine in Biotech IPOs?
This article was originally published in Start Up
Executive Summary
First, investors over-reacted to the Clinton/Blair statement on open access to gene data. If that wasn't enough, the entire technology sector tanked following Microsoft's bad news. Biotech IPOs have suffered from the recent market volatility.